Ethnic, racial, and sex-specific factors are important in cardiovascular pharmacotherapeutics.
Caracciolo
Vincent J
VJ
Shaefer
Benjamin M
BM
Charney
Pamela
P
D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics; D000959:Antihypertensive Agents / Q000493:pharmacokinetics; D044383:Black People / Q000235:genetics*; D002317:Cardiovascular Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000201:enzymology / Q000208:ethnology / Q000235:genetics / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D006801:Humans; D008790:Metoprolol / Q000493:pharmacokinetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D015995:Prevalence; D012737:Sex Factors; D014700:Verapamil / Q000493:pharmacokinetics; D044465:White People / Q000235:genetics*
D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D003577:Cytochrome P-450 Enzyme System; D014700:Verapamil; C104464:CYP3A protein, human; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; D008790:Metoprolol